Anhui Orivie Technology (300692.SZ) plans to jointly invest with Hefei Guotou to acquire control of Junke Zhengyuan.

Anhui Orivie Technology (300692.SZ) announced that its wholly-owned subsidiary, Zhongfu Junke Zhengyuan (Anhui) Biomedical Technology Co., Ltd. (abbreviated as "Zhongfu Zhengyuan"), plans to sign a "Share Transfer Agreement" and its supplementary agreements with Junke Zhengyuan (Beijing) Drug Research Co., Ltd. (abbreviated as "Junke Zhengyuan") and related parties to acquire control of Junke Zhengyuan and its integrated CRO assets. The total investment for this acquisition is 1 billion yuan, which will be raised through a combination of self-funding, external institutional investment, and bank merger loans. To leverage the professional resources and investment capabilities of specialized investment institutions and expedite the acquisition process of Junke Zhengyuan, the company intends to jointly invest in acquiring control of Junke Zhengyuan with Hefei State-owned Capital Venture Investment Co., Ltd. (abbreviated as "Hefei Guotou"). Zhongfu Zhengyuan plans to increase its registered capital from 100 million yuan to 400 million yuan in three phases. In the first phase, the company or designated qualified entities (if any) will contribute a total of 104 million yuan, while the Hefei Guotou-managed fund: Hefei Jiantou Emerging Industries Equity Investment Fund Partnership (Limited Partnership) (abbreviated as "Emerging Industries Fund") and other investors (if any) will contribute a total of 196 million yuan. After the first phase of capital increase is completed, the company will hold 51% of Zhongfu Zhengyuans equity, while the Emerging Industries Fund and other investors (if any) will hold 49% of Zhongfu Zhengyuans equity. Innovative drugs and medical devices, as well as CXO, are one of the core business directions of the company's future development strategy. Junke Zhengyuan is a leading enterprise in the field of innovative drug bioanalysis in China, with its core business providing clinical sample bioanalysis testing services to pharmaceutical R&D companies. This investment is one of the company's initiatives to strategically position itself in the innovative drugs, medical devices, and CXO-related industries. By obtaining control of Junke Zhengyuan, the company aims to continuously advance its innovative drugs, medical devices, and CXO business.